Efficacy and safety of infliximab in psoriatic patients over the age of 65

Chiricozzi, Andrea; Pavlidis, Athanasios; Dattola, Annunziata; Bianchi, Luca; Chimenti, Maria Sole; Fida, Monika; Saraceno, Rosita

doi:10.1080/14740338.2016.1226279

Cited by 22 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 A retrospective case series on the use of infliximab on 27 patients revealed a rapid and stable response over time, even though a notable discontinuation rate, mostly due to lack of efficacy and occurrence of AEs, was recorded. 17 With regard to IL-12/23 inhibitors, ustekinumab showed a clearance rate in elderly patients that was similar or slightly lower than that of younger patients, as well as low discontinuation and AE rates. 9,18,19 With respect to more recently approved drugs such as IL-17A inhibitors, we have previously reported that ixekizumab appears to be extremely effective and safe in elderly patients with psoriasis through a 1-year real-life observational study; 100% reduction in PASI (PASI100) response was reached in 81.2% of patients at week 48 without serious AEs or AEs requiring drug discontinuation.…”

Section: Discussionmentioning

confidence: 95%

Real‐life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2‐year period

et al. 2020

View full text Add to dashboard Cite

Background The prevalence of psoriasis is increasing among older people. Elderly patients with psoriasis represent a challenge for dermatologists owing to multiple comorbidities, polypharmacy and immune senescence, which lead to an increased possibility of adverse events (AEs), drug interactions and susceptibility to cancers and infections. Therefore, conventional systemic therapies are often contraindicated, with biologics appearing as the mainstay for moderate‐to‐severe disease. However, the data on efficacy and safety of biologics in older people are scant. Aim To evaluate the efficacy and safety of secukinumab in elderly patients with psoriasis over a 2‐year period. Methods A real‐life retrospective observational study was performed on patients aged ≥ 65 years with moderate‐to‐severe plaque psoriasis who were treated with secukinumab at the Psoriasis Care Unit of the University of Naples Federico II, Italy from June 2016 to June 2019. Results Mean Psoriasis Area Severity Index (PASI) reduced from 11.4 ± 6.3 at baseline to 2.1 ± 1.7 at week 24 and 1.7 ± 1.9 at week 96 (P < 0.001 for all follow‐up visits), with a final mean PASI reduction of 85.1%. A similar trend was noted for body surface area (BSA), with baseline value of 27.5 ± 15.7 decreasing to 6.8 ± 5.0 at week 24, and to 3.3 ± 2.5 at week 96 (P < 0.001 at all follow‐up visits), with a final mean BSA score reduction of 88.0%. Registered AEs did not lead to secukinumab discontinuation, except in one patient (3.4%). Conclusion Secukinumab seems to be a safe and effective treatment for elderly patients with psoriasis, who frequently have multiple comorbidities, polypharmacy and multiple failures with previous systemic treatments including biologics.

show abstract

Section: Discussionmentioning

confidence: 95%

Real‐life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2‐year period

et al. 2020

View full text Add to dashboard Cite

show abstract

“…and safety of ustekinumab in elderly patients with psoriasis, 10,11 and Chiricozzi et al 12 reported a rapid PASI score reduction and maintenance in the long term in 27 elderly patients under treatment with infliximab. The German Psoriasis Registry PsoBest reported no differences in biologics prescription in patients aged 65 or over and patients aged 35-64.…”

Section: Discussionmentioning

confidence: 99%

“…A previous retrospective study evaluated the long‐term efficacy and safety profile of etanercept and adalimumab, in the treatment of elderly patients affected by plaque‐type psoriasis and psoriatic arthritis . Similarly, Japanese and Italian authors reported the efficacy and safety of ustekinumab in elderly patients with psoriasis, and Chiricozzi et al . reported a rapid PASI score reduction and maintenance in the long term in 27 elderly patients under treatment with infliximab.…”

Section: Discussionmentioning

confidence: 99%

Elderly psoriatic patients under biological therapies: an Italian experience

Ricceri

Bardazzi

Chiricozzi

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

To date, our study represents the widest experience on the use of biological drugs in elderly psoriatic patients. We found that all biologics for psoriasis showed a great efficacy also in elderly people, and the rate and the type of adverse effects were similar to the younger patients. In conclusion, the age alone should not limit our therapeutic options. Further observational study using multiple data sources is needed to evaluate long-term effectiveness and safety for elderly psoriatic patients.

show abstract

“…In other studies PASI 75 responses range from 40 to >90%. All biologics efficacy rates is superior compared to other therapies (Chiricozzi et al, ; Vilarrasa et al, ). Biologics are now a major progress in treatment of moderate to severe psoriasis.…”

Section: Discussionmentioning

confidence: 99%

“…In other studies there are mixed levels of evidence for the long‐term efficacy of biologics. They conclude that treatment adherence and safety profile is good (Chiricozzi et al, ).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of biologic therapies in psoriasis vulgaris

Mala

Fida

Jorgaqi

et al. 2019

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Psoriasis is a chronic, immune‐mediated skin disease that also has systemic manifestations. Biologic preparates: Adalimumab, Etanercept, and Infliximab are licensed for psoriasis vulgaris treatment in Albania. To compare the efficacy of biologic therapies used for psoriasis based in our experience. A cohort prospective study during the years 2016–2018 at UHC “Mother Teresa” Tirana. In the study took place 78 patient diagnosed with psoriasis and treated with biologic therapies. Psoriasis Area Severity Index (PASI) 50 and PASI 75 index were the parameters of response outcomes. PASI 50 was achieved for 6.8, 7.02, and 7.2 weeks in patients with Etanercept, Adalimumab, and Infliximab respectively and PASI 75 for 12.8, 11.4, and 11.42 weeks. X2 = 0.076, p > .05, nonsignificant difference. PASI 50 was achieved in 27.2% of subject treated with Etanercept, 67.4% Adalimumab, and 55.5% with Infliximab for the weeks mentioned above. Meanwhile PASI 75 was achieved in 45.4% of subject treated with Etanercept, 61.7% Adalimumab, and 25% with Infliximab. X2 = 15.28, p < .05, significant difference. Biologics have revolutionized the treatment of psoriasis. To select the most appropriate agent for patient, should be considered multiple factors including adverse effects, tolerance, patient preference, cost, and mode of administration.

show abstract

Efficacy and safety of infliximab in psoriatic patients over the age of 65

Abstract: Our data suggest that long-term treatment with infliximab is effective and safe in patients over 65 years old and that IV therapy is also associated with a high compliance.

Cited by 22 publications

References 18 publications

Real‐life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2‐year period

Real‐life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2‐year period

Elderly psoriatic patients under biological therapies: an Italian experience

Efficacy of biologic therapies in psoriasis vulgaris

Contact Info

Product

Resources

About